Compare Quest Diagnostics Inc (DGX) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Under Armour Inc Class A — how do they compare? Quest Diagnostics Inc trades at $205.18 (market cap $22.80B), while Under Armour Inc Class A trades at $6.86 (market cap $2.79B). The key difference: Quest Diagnostics Inc is far larger — about 8.2× Under Armour Inc Class A's market cap, and Quest Diagnostics Inc pays a 1.67% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals.
| DGX | UAA | |
|---|---|---|
Market Cap | $22.80B | $2.79B |
Sector | Health | Consumer Cyclical |
52-Week High | $216.02 | $8.14 |
52-Week Low | $166.42 | $4.17 |
Enterprise Value | $28.82B | $4.42B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Under Armour (UAA) trades at $6.75, down 0.59% on the day, with a mixed technical picture showing bullish moving averages but overbought RSI signals. Fundamentally, the company reported a net loss of $201.27 million in 2025 despite beating EPS expectations in two recent quarters, with revenue declining to $5.16 billion. Analyst sentiment is cautious with a consensus price target of $5.96, below the current price, and news highlights ongoing challenges in North America offset by international growth.
The outlook remains challenging with weak guidance for FY2027 and margin pressure, though international expansion and a recent Dodge collaboration offer potential catalysts. Key risks include persistent North American weakness, rising costs, and high debt levels. Investors face a stock with negative profitability metrics trading above analyst targets, suggesting limited near-term upside absent a significant operational turnaround.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
